Did you know?

Exact Sciences Corporation EXAS recently presented modeling data that shows Cologuard (mt-sDNA) as the most cost-effective colorectal cancer (CRC) detection and screening option at the 2021 ...Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Stock Market Today: Stocks lower, Nvidia and Tesla slide, Gold retreats from record high. Investors are betting on at least five Fed interest-rate cuts next ...At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new October 28th contracts and identified one put and one call contract of particular ...Exact Sciences ( EXAS 8.39%) can't claim all the credit, but the non-invasive cancer tests that it markets play an important role. The company's cancer tests screened around 4 million people in ...EXAS earnings call for the period ending March 31, 2023. Image source: The Motley Fool. Exact Sciences ( EXAS 0.14% ) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ETExact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995.Apr 10, 2023 · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ... 17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...Who is on Exact Sciences's Insider Roster? The list of insiders at Exact Sciences includes Brian Baranick, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella. Learn more on insiders at EXAS.Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...Exact Sciences' (NASDAQ:EXAS) potential is so misunderstood and undervalued that we believe that EXAS probably has an upside of 100%-300% over the next twelve months based on the prospects of its ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ...The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.Exact Sciences Corporation EXAS continues to makNov 1, 2023 · MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact May 15, 2023 · Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ... Apr 26, 2021 · Exact Sciences Corporation Exact Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off last year's report dates. Learn more on EXAS's earnings history. In summary, the author projects Exact Sciences Cor

Texas Instruments Incorporated Common Stock (TXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ...Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...

Jul 25, 2023 · One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ... Shares of EXAS stock opened at $67.03 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.13 and a current ratio of 2.41. The firm has a market cap of $12.12 billion, a ...20 Okt 2023 ... PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cance. Possible cause: Exact Sciences Corporation (NASDAQ:EXAS) is a Wisconsin-based molecular g.